About Hemosonics
Hemosonics is a company based in Charlottesville (United States) founded in 2004 was acquired by Diagnostica Stago in May 2017.. Hemosonics has raised $24.92 million across 9 funding rounds from investors including HHS, Diagnostica Stago and U.S. Air Force. Hemosonics has completed 1 acquisition, including Diagnostica Stago. Hemosonics offers products and services including Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program. Hemosonics operates in a competitive market with competitors including Perosphere Technologies, Atantares, Stasys, HemoSense and ClotChip, among others.
- Headquarter Charlottesville, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hemosonics, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$24.92 M (USD)
in 9 rounds
-
Latest Funding Round
$15 M (USD), Series B
Feb 14, 2017
-
Investors
HHS
& 3 more
-
Employee Count
Employee Count
- Investments & Acquisitions
-
Acquired by
Diagnostica Stago
(May 30, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hemosonics
Hemosonics offers a comprehensive portfolio of products and services, including Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Device for viscoelastic testing of blood coagulation in surgical settings.
Cartridge for coagulation evaluations in point-of-care applications.
Cartridge to assess hypocoagulable and hypercoagulable conditions in trauma.
Kits for ensuring accuracy in hemostasis testing procedures.
Program for external quality assessment of hemostasis testing.
Unlock access to complete
Funding Insights of Hemosonics
Hemosonics has successfully raised a total of $24.92M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $15.0M
-
First Round
First Round
(25 Jun 2010)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2017 | Amount | Series B - Hemosonics | Valuation |
investors |
|
| Aug, 2016 | Amount | Series A - Hemosonics | Valuation |
investors |
|
| Aug, 2015 | Amount | Grant - Hemosonics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hemosonics
Hemosonics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Diagnostica Stago and U.S. Air Force. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Aerial defense and operations are conducted for national security.
|
Founded Year | Domain | Location | |
|
Research on heart, lung, blood, and sleep disorders is conducted.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hemosonics
Hemosonics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Diagnostica Stago. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
A portfolio of hemostasis and coagulation diagnostic products is manufactured.
|
1998 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Hemosonics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hemosonics Comparisons
Competitors of Hemosonics
Hemosonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Perosphere Technologies, Atantares, Stasys, HemoSense and ClotChip, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Point-of-care coagulation diagnostics and drug delivery systems are developed.
|
|
| domain | founded_year | HQ Location |
Developer of precision medicines & smart diagnostic devices by fusing biochip and AI technologies
|
|
| domain | founded_year | HQ Location |
Provider of POC device for analyzing blood clotting disorders and platelet dysfunction
|
|
| domain | founded_year | HQ Location |
Rapid Point-of-Care Coagulation analyzer
|
|
| domain | founded_year | HQ Location |
Portable tests for blood coagulation analysis are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hemosonics
Frequently Asked Questions about Hemosonics
When was Hemosonics founded?
Hemosonics was founded in 2004 and raised its 1st funding round 6 years after it was founded.
Where is Hemosonics located?
Hemosonics is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Is Hemosonics a funded company?
Hemosonics is a funded company, having raised a total of $24.92M across 9 funding rounds to date. The company's 1st funding round was a Grant of $1M, raised on Jun 25, 2010.
What does Hemosonics do?
HemoSonics is a privately held medical device company founded to develop and bring to market innovative in vitro diagnostics to characterize hemostasis in a variety of clinical settings. These systems employ a patented approach named sonorheometry (SR). The products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. The company claims that this approach makes their system easier to operate and interpret than existing products. Potential clinical applications include trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery among others. This technology has undergone clinical and laboratory testing supported by a series of academic and business grants from the National Institutes of Health, the Wallace H. Coulter Foundation for Translational Research, the Office of Naval Research, and private investors. Sonorheometry has been demonstrated in a series of peer-reviewed scientific publications and has undergone both laboratory and clinical evaluation. Standalone prototypes are undergoing further clinical and laboratory evaluation. HemoSonics LLC is developing a POC instrument, the Global Hemostasis Analyzer (GHA) that can quantify the function of the four hemostatic components, enabling correct selection of treatment. The Quantra is based on sonorheometry (SR), a novel technology able to assess not only time to clot (dependent upon the plasma coagulation factors) but also clot formation rate (dependent upon fibrinogen), clot stiffness (dependent upon fibrinogen and platelets), and time to lysis (dependent upon clot-dissolving proteins).
Who are the top competitors of Hemosonics?
Hemosonics's top competitors include Perosphere Technologies, Atantares and Stasys.
What products or services does Hemosonics offer?
Hemosonics offers Quantra® Hemostasis Analyzer, QPlus® Cartridge, QStat® Cartridge, Quantra® Quality Control Kits, and Qualiris EQA Proficiency Program.
How many acquisitions has Hemosonics made?
Hemosonics has made 1 acquisition, including Diagnostica Stago.
Who are Hemosonics's investors?
Hemosonics has 4 investors. Key investors include HHS, Diagnostica Stago, U.S. Air Force, and National Heart, Lung, and Blood Institute.